Role of lipoprotein lipase in plasma triglyceride removal.
Intravenous injections of anti-lipoprotein lipase serunis quantitatively block the catabolism of very low density lipoprotein (VLDL) and portomicron triglyceride and specifically inhibit triglyceride transport into ovarian follicles. The immunological studies presented provide information on the site of action of lipoprotein lipase (LPL). In the anti-LPL serum-treated animals initial plasma triglyceride accumulation occurs at the time of antiserum injection. This instantaneous inhibition of triglyceride removal provides direct evidence that the functional LPL responsible for VLDL and portomicron triglyceride hydrolysis is located in sites within the plasma compartment readily accessible to immunoglobulins. In vitro immunological studies show that the adipose, heart, ovarian, and liver LPL share common immunological determinants. Biochemical studies on highly purified heart and adipose LPL suggest that these enzymes have identical protein moieties.
D000273:Adipose Tissue / Q000201:enzymology; D000818:Animals; D005260:Female; D007106:Immune Sera; D008071:Lipoprotein Lipase / Q000276:immunology / Q000502:physiology*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D009865:Oocytes / Q000378:metabolism; D011200:Poultry / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood*
D007106:Immune Sera; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D008071:Lipoprotein Lipase